Digital x-ray may represent the future for Swiss x-ray manufacturerSwissray, but it is conventional radiography that is the company'sbread and butter for the time being. Swissray announced this monththat it has signed an agreement to supply conventional
Digital x-ray may represent the future for Swiss x-ray manufacturerSwissray, but it is conventional radiography that is the company'sbread and butter for the time being. Swissray announced this monththat it has signed an agreement to supply conventional x-ray equipmentto a major multinational OEM in a deal valued at $40 million.
Swissray, of Hitzkirch, Switzerland, burst on the U.S. medicalimaging scene at last year's Radiological Society of North Americameeting with AddOn-Bucky, a device to digitize conventional x-rayexams (SCAN 12/13/95). Swissray began installing the first AddOn-Buckyunits earlier this year in Europe.
Swissray has not neglected its conventional x-ray program,however, as evidenced by this month's deal. According to the termsof the agreement, Swissray will supply its radiography productsto the OEM, which will market the devices under its own label.Swissray said that the terms of the agreement precluded it fromdisclosing the name of the OEM.
Swissray will supply equipment to the OEM for the next fourand a half years, with initial shipments to be delivered in thenext 12 months valued at over $8 million.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.